Crescita Therapeutics Inc (CRRTF) Fair Value & Analysis
Healthcare · US · Market cap $10.4M
Crescita Therapeutics Inc
CRRTF · US
Fair value as of: Jun 24, 2026
From 14 valuation models · updated 18 days ago
Fair value updated Jun 24, 2026 — revised from $0.8500 to $0.8100 (−4.7%) since Jun 23, 2026. Share price −2.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0210 – $0.5731 · fair‑value band $0.7000 – $0.9100 · the $0.5587 price screens below the $0.8100 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Crescita Therapeutics Inc (CRRTF) currently trades at $0.5587, while our model-based Fair Value estimate is $0.8100 — implying the stock looks roughly 45.0% undervalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Crescita Therapeutics Inc generated revenue of $23.2M at a net margin of -1.4%. Revenue grew 59.4% year over year. It earns a return on equity of -2.2%. The balance sheet holds a net cash position of $8.2M. Fundamentals as of Jun 24, 2026
Our scenario range runs from $0.7000 (bear case) to $0.9100 (bull case); at $0.5587, the current price sits below that range. The share trades about 3% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at 45%, CRRTF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhancers and DuraPee that supports the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures. Its non-prescription portfolio offers dermocosmetic products, such as face creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud and Aquafolia brands; and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Crescita Therapeutics Inc reported revenue of $21.1M in FY2025 versus $16.8M in FY2021, a compound +5.9%/yr. Reported net income was −$91.9K in FY2025.
Is CRRTF fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Crescita Therapeutics Inc (CRRTF) undervalued?
What is the fair value of CRRTF?
What is the quality score of CRRTF?
What is the revenue of Crescita Therapeutics Inc (CRRTF)?
What is the net profit margin of CRRTF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Crescita Therapeutics Inc analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.